Pathoetiology of Levator Ani Syndrome and Its Treatment With Translumbosacral Neuromodulation Therapy

Am J Gastroenterol. 2023 Dec 1;118(12):2242-2246. doi: 10.14309/ajg.0000000000002394. Epub 2023 Jul 7.

Abstract

Introduction: The pathoetiology and treatment of levator ani syndrome (LAS) remain unclear.

Methods: We evaluated pathophysiology using translumbosacral motor-evoked potentials and anorectal manometry in patients with LAS and compared with healthy controls. A cohort underwent translumbosacral neuromodulation therapy (TNT).

Results: Lumbar and sacral motor-evoked potential latencies were prolonged in 32 patients with LAS compared with 31 controls ( P < 0.013), with higher prevalence of anal neuropathy ( P = 0.026). TNT improved anorectal pain ( P = 0.003) and neuropathy ( P < 0.02) in 13 patients with LAS.

Discussion: Patients with LAS demonstrate significant lumbosacral neuropathy that may cause anorectal pain. TNT improved anorectal pain and neuropathy, providing a novel therapeutic option.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anal Canal
  • Anus Diseases* / therapy
  • Fecal Incontinence* / therapy
  • Humans
  • Pain / drug therapy

Supplementary concepts

  • Levator syndrome